10 Days to go..., page-25

They already released some initially positive news on the 22nd September,
Hopefully this has continued to progress positively since then,
　
Study update

23 subjects have been recruited from study sites in Australia and the UK, up from 18 subjects at 22 August. Two subjects recruited earlier in the study have withdrawn due to illness (unrelated to the device).

The Company will continue to recruit subjects beyond the initial 20 subject target to gather additional valuable clinical experience and to account for subject loss due to factors such as withdrawal on clinical grounds prior to implantation or protocol ineligibility.

Recruitment efforts for the global study continue to accelerate across all 10 activated centres in Australia, the UK and US. Data gathered to date will contribute to the 20-subject Supplemental Data Request to secure CE Marking, Oncosil’s immediate focus.

Of the 23-subject study group, 10 subjects have now been successfully implanted with the OncoSil™ device, up from 4 subjects at 31 July.

Positive interim data relating to tumour response and disease control has been received from subjects implanted during the current phase of the programme. Study investigators have been encouraged by the clinical data that have emerged so far from the study.
​

Oncosil intends to share a study progress update at the European Association of Nuclear Medicine in Vienna on 21 October and will share an update with the market accordingly.